OneMedNet Partners with Risorius to Advance EEG-Based Digital Biomarkers for CNS Research
核心洞察
OneMedNet Corporation (搜索) announced a strategic data licensing agreement with neurotechnology company Risorius to provide large-scale EEG (搜索) and PSG (搜索) waveform data for digital biomarker development.
The partnership will deliver multimodal neurological data over three months to support Risorius's AI Co-Scientist platform for CNS research across neurology, psychiatry, and sleep disorders.
The agreement represents millions of dollars in incremental recurring revenue for OneMedNet and demonstrates growing demand for regulatory-grade real-world data in AI-driven healthcare innovation.
OneMedNet Corporation (搜索) has entered into a strategic data licensing agreement with Risorius Co., Ltd. (搜索), a neurotechnology company developing EEG (搜索)-based digital biomarkers and AI-powered research platforms for central nervous system indications. The partnership, announced February 24, 2026, represents a significant expansion of OneMedNet's subscription contracts, adding multi-year agreements worth millions of dollars in incremental recurring revenue.
The agreement was executed in record time following the companies' initial meeting, with data delivery already underway through a three-month licensing project. Under the terms, Risorius has licensed access to large-scale electroencephalography (EEG (搜索)) and polysomnography (PSG (搜索)) waveform data paired with clinically meaningful context and longitudinal follow-up data.
Advancing CNS Digital Biomarker Development
The datasets will support Risorius's internal research and development efforts, including model development and validation for EEG (搜索)-based digital biomarkers. The company is developing an AI Co-Scientist platform designed to support neurological and psychiatric clinical studies, particularly for pharmaceutical companies and academic hospitals working across neurology, psychiatry, and sleep medicine.
"Risorius' rapid decision to partner with OneMedNet underscores the value of our regulatory-grade neuro data and continuous delivery model," stated Aaron Green, CEO and President of OneMedNet. "Real-World EEG (搜索) and PSG (搜索) waveform data, when paired with longitudinal clinical results, are foundational to the research and development of next-generation solutions focused on solving central nervous system disorders."
Strategic Selection Criteria
Risorius selected OneMedNet based on several key differentiators that aligned with their R&D requirements. These included access to multimodal data featuring high-fidelity EEG (搜索) and PSG (搜索) waveforms paired with longitudinal clinical data, substantial data volume to support potential program expansion, a transparent and structured curation process, and a well-organized de-identification workflow.
The practical subscription licensing approach enabled Risorius to move quickly from evaluation to execution, reflecting what both companies describe as strong commercial alignment and clear product-market fit.
"We chose OneMedNet because of the clear alignment with our scientific and operational needs," explained Sangyoon Bae, CEO of Risorius. "The combination of well-curated EEG (搜索) and PSG (搜索) waveform data, meaningful longitudinal follow-up, and a scalable licensing model provides the foundation we need to accelerate internal R&D, model validation, and development of our AI Co-Scientist platform."
Market Positioning and Growth Strategy
The partnership highlights continued momentum in OneMedNet's data licensing strategy and expansion within the high-growth neuro and CNS vertical. The company operates through its iRWD™ platform, which harnesses data from over 2,130 healthcare sites, spanning rare diseases, oncology, cardiology, and neurological conditions.
According to Green, the agreement reflects growing demand from AI-native companies seeking scalable, high-quality datasets to power digital biomarker development and advanced analytics. The efficient commercial execution demonstrated by rapid contract conversion positions OneMedNet as a trusted infrastructure partner enabling AI innovation in healthcare.
Technology Platform Development
Risorius is developing scalable pipelines for signal processing, quality control, and multimodal analytics to enable biomarker discovery, treatment response modeling, and evidence generation from real-world clinical data. The company's AI Co-Scientist platform is designed to help research teams optimize analysis workflows for CNS research and accelerate hypothesis testing and clinical studies.
By translating EEG (搜索) signal data into actionable insights, Risorius aims to support faster, more data-driven decision-making for CNS research and care delivery. The partnership with OneMedNet is expected to contribute to the company's technological competitiveness as it accelerates database construction and R&D projects.